Annual CFF
$27.01 M
-$175.74 M-86.68%
December 31, 2024
Summary
- As of March 13, 2025, KRYS annual cash flow from financing activities is $27.01 million, with the most recent change of -$175.74 million (-86.68%) on December 31, 2024.
- During the last 3 years, KRYS annual CFF has fallen by -$320.67 million (-92.23%).
- KRYS annual CFF is now -92.23% below its all-time high of $347.69 million, reached on December 31, 2021.
Performance
KRYS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$2.43 M
-$937.00 K-27.85%
December 31, 2024
Summary
- As of March 13, 2025, KRYS quarterly cash flow from financing activities is $2.43 million, with the most recent change of -$937.00 thousand (-27.85%) on December 31, 2024.
- Over the past year, KRYS quarterly CFF has dropped by -$8.15 million (-77.06%).
- KRYS quarterly CFF is now -98.80% below its all-time high of $202.07 million, reached on December 31, 2021.
Performance
KRYS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$27.01 M
-$191.00 K-0.70%
December 31, 2024
Summary
- As of March 13, 2025, KRYS TTM cash flow from financing activities is $27.01 million, with the most recent change of -$191.00 thousand (-0.70%) on December 31, 2024.
- Over the past year, KRYS TTM CFF has dropped by -$184.84 million (-87.25%).
- KRYS TTM CFF is now -92.23% below its all-time high of $347.69 million, reached on December 31, 2021.
Performance
KRYS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
KRYS Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -86.7% | -77.1% | -87.3% |
| 3 y3 years | -92.2% | -20.9% | -23.6% |
| 5 y5 years | -74.9% | -20.9% | -23.6% |
KRYS Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -92.2% | at low | -98.8% | +548.0% | -92.2% | at low |
| 5 y | 5-year | -92.2% | at low | -98.8% | +548.0% | -92.2% | at low |
| alltime | all time | -92.2% | +731.5% | -98.8% | +450.4% | -92.2% | +8904.7% |
Krystal Biotech Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $27.01 M(-86.7%) | $2.43 M(-27.8%) | $27.01 M(-0.7%) |
| Sep 2024 | - | $3.37 M(-68.4%) | $27.20 M(-26.9%) |
| Jun 2024 | - | $10.64 M(+0.5%) | $37.23 M(-82.4%) |
| Mar 2024 | - | $10.58 M(+304.1%) | $211.86 M(+4.5%) |
| Dec 2023 | $202.75 M(+473.6%) | $2.62 M(-80.4%) | $202.75 M(-0.2%) |
| Sep 2023 | - | $13.39 M(-92.8%) | $203.20 M(+5.9%) |
| Jun 2023 | - | $185.27 M(>+9900.0%) | $191.93 M(+413.7%) |
| Mar 2023 | - | $1.47 M(-52.0%) | $37.36 M(+5.7%) |
| Dec 2022 | $35.35 M(-89.8%) | $3.07 M(+44.8%) | $35.35 M(-84.9%) |
| Sep 2022 | - | $2.12 M(-93.1%) | $234.35 M(+0.3%) |
| Jun 2022 | - | $30.70 M(-5764.2%) | $233.74 M(+15.2%) |
| Mar 2022 | - | -$542.00 K(-100.3%) | $202.84 M(-41.7%) |
| Dec 2021 | $347.69 M(+194.6%) | $202.07 M(>+9900.0%) | $347.69 M(+138.5%) |
| Sep 2021 | - | $1.51 M(-857.8%) | $145.75 M(+0.9%) |
| Jun 2021 | - | -$199.00 K(-100.1%) | $144.41 M(-44.9%) |
| Mar 2021 | - | $144.30 M(>+9900.0%) | $262.08 M(+122.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | $118.02 M(+9.8%) | $141.00 K(-15.1%) | $118.02 M(-0.1%) |
| Sep 2020 | - | $166.00 K(-99.9%) | $118.18 M(-9.9%) |
| Jun 2020 | - | $117.47 M(>+9900.0%) | $131.18 M(+21.8%) |
| Mar 2020 | - | $243.00 K(-18.7%) | $107.73 M(+0.2%) |
| Dec 2019 | $107.53 M(+45.6%) | $299.00 K(-97.7%) | $107.53 M(-37.3%) |
| Sep 2019 | - | $13.17 M(-86.0%) | $171.51 M(+2.2%) |
| Jun 2019 | - | $94.02 M(>+9900.0%) | $167.90 M(+127.3%) |
| Mar 2019 | - | $40.00 K(-99.9%) | $73.88 M(+0.0%) |
| Dec 2018 | $73.85 M(+42.6%) | $64.29 M(+573.2%) | $73.85 M(+732.9%) |
| Sep 2018 | - | $9.55 M(>+9900.0%) | $8.87 M(-82.1%) |
| Jun 2018 | - | $4000.00(-33.3%) | $49.48 M(-3.9%) |
| Mar 2018 | - | $6000.00(-100.9%) | $51.47 M(-0.6%) |
| Dec 2017 | $51.77 M(+1493.4%) | -$693.00 K(-101.4%) | $51.77 M(-1.3%) |
| Sep 2017 | - | $50.16 M(+2409.4%) | $52.46 M(+2181.9%) |
| Jun 2017 | - | $2.00 M(+566.3%) | $2.30 M(+666.3%) |
| Mar 2017 | - | $300.00 K | $300.00 K |
| Dec 2016 | $3.25 M | - | - |
FAQ
- What is Krystal Biotech annual cash flow from financing activities?
- What is the all time high annual CFF for Krystal Biotech?
- What is Krystal Biotech annual CFF year-on-year change?
- What is Krystal Biotech quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Krystal Biotech?
- What is Krystal Biotech quarterly CFF year-on-year change?
- What is Krystal Biotech TTM cash flow from financing activities?
- What is the all time high TTM CFF for Krystal Biotech?
- What is Krystal Biotech TTM CFF year-on-year change?
What is Krystal Biotech annual cash flow from financing activities?
The current annual CFF of KRYS is $27.01 M
What is the all time high annual CFF for Krystal Biotech?
Krystal Biotech all-time high annual cash flow from financing activities is $347.69 M
What is Krystal Biotech annual CFF year-on-year change?
Over the past year, KRYS annual cash flow from financing activities has changed by -$175.74 M (-86.68%)
What is Krystal Biotech quarterly cash flow from financing activities?
The current quarterly CFF of KRYS is $2.43 M
What is the all time high quarterly CFF for Krystal Biotech?
Krystal Biotech all-time high quarterly cash flow from financing activities is $202.07 M
What is Krystal Biotech quarterly CFF year-on-year change?
Over the past year, KRYS quarterly cash flow from financing activities has changed by -$8.15 M (-77.06%)
What is Krystal Biotech TTM cash flow from financing activities?
The current TTM CFF of KRYS is $27.01 M
What is the all time high TTM CFF for Krystal Biotech?
Krystal Biotech all-time high TTM cash flow from financing activities is $347.69 M
What is Krystal Biotech TTM CFF year-on-year change?
Over the past year, KRYS TTM cash flow from financing activities has changed by -$184.84 M (-87.25%)